TheStreet's Adam Feuerstein wants to know who you think has been the worst biotech CEO of 2011. There have been several missteps in the world of biotech this year, Feuerstein says, like "a desperate, $11 billion Hail Mary acquisition, two botched drug launches, a clueless, tin-eared investor relations strategy, and an expensive and quixotic quest to develop a product no one needs."